Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Here at the London School of Hygiene and Tropical Medicine we are running a project called the Vaccine Confidence Project and we have a global surveillance monitoring information around the world on media, social media, all sorts of information, reports from governments, UN, other sources, looking for any what we call “signals” of public distrust or concerns that come up.
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
'Evil' scientists, deadly viruses and terrorist plots are usually the preserve of Hollywood blockbusters. But when it comes to pandemic influenza, it is the stuff of real life. As controversy about research into the H5N1 bird flu virus continues, a new paper argues for a complete overhaul of current approaches to pandemic preparedness.
At least one in five people in countries for which data are available were infected with influenza during the first year of the 2009 H1N1 pandemic, according to a new study.
Norwegian pregnant women who received a vaccine against the 2009 H1N1 influenza virus showed no increased risk of pregnancy loss, while pregnant women who experienced influenza during pregnancy had an increased risk of miscarriages and still births, a study has found. The study suggests that influenza infection may increase the risk of fetal loss.
The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.
NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.
Researchers report for the first time the seroprevalence of three strains of avian influenza viruses in pigs in southern China, but not the H5N1 avian influenza virus. Their research, published online ahead of print in the Journal of Clinical Microbiology, has implications for efforts to protect the public health from pandemics.
CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2012.
College football and basketball games may provide more than a way for students to show school spirit - they could help prevent the flu.
CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).
CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
In 2009, a new strain of influenza, or flu, virus emerged and spread rapidly to many countries around the world. It was declared a pandemic by the World Health Organization (WHO) in June 2009.
CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.
Sanofi Pasteur, the vaccines division of Sanofi, presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV).
A new model of influenza transmission, published in BioMed Central's open access journal BMC Medicine, using more detailed information about patterns and severity of infection than previous models, finds that cases and transmission rates of H1N1 during the 2009-2010 flu pandemic have been underestimated. This model can provide a more robust and accurate real-time estimate of infection during a pandemic, which will help health services prepare and respond to future outbreaks.
With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.
Mathematicians have developed a powerful tool to quantify the spread and infectiousness of viruses like the pandemic H1N1 flu strain, which can be used together with modern laboratory techniques to help the healthcare system plan its response to disease outbreaks.
The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.